Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Gene Transfer Technology May Lead To HIV Vaccine
A research team may have broken the impasse that has frustrated HIV vaccine researchers by using an unconventional approach that bypasses the usual vaccine development path. Using gene transfer technology to produces molecules that block infection, the scientists protected monkeys from infection by a virus closely related to HIV -- the simian immunodeficiency virus, or SIV. "We used a leapfrog strategy, bypassing the natural immune system response that was the target of previous HIV and SIV vaccine candidates," explains study leader Philip R. Johnson, MD, chief scientific officer at The Children"s Hospital of Philadelphia and professor of pediatrics at the University of Pennsylvania. Johnson and colleagues reported their work in Nature Medicine Most attempts at developing an HIV vaccine have used substances aimed at stimulating the body"s immune system to produce antibodies that would eliminate the virus before or after it infected cells. In clinical trials, however, these vaccines have not elicited protective immune responses, just as the body fails on its own to produce an effective response during natural HIV infection.
generic viagra online
New Risk Factor Gene For Rheumatoid Arthritis Identified By Researchers
Scientists at The Feinstein Institute for Medical Research and a team of collaborators from across the country have identified a new risk factor gene for rheumatoid arthritis. The paper will be published in Nature Genetics and the finding brings light to the nature of the disease. The gene, dubbed REL, is a member of the NF-íşB family, important transcription factors that have many roles in the body. The NF-íşB family seems to have a big hand in regulating the body"s immune response as well.
News of the day
GMC Reviews Guidance For Doctors On Involving Patients In Research
The GMC is calling for people to give their input on guidance that doctors must follow when filming or making audio recordings of patients and undertaking research.
Sexual Health

Cole Foundation Injects $2.5 Million To Bolster Leukemia Research

Canada has received new support to recruit some of its best minds in pediatric leukemia research, thanks to the Cole Foundation. The family foundation has generously pledged $2.5 million to support up-and-coming, Montreal-based researchers at the Universitçİ de Montrçİal, McGill University and the Universitçİ du Quçİbec"s Institut national de la recherche scientifique - Institut Armand-Frappier. The Cole Foundation investment will include: * Two Cole Foundation Mid-Career Grants totalling $620,000, allotted over four years, to permit the Universitçİ de Montrçİal and McGill University to hire one scientist each. * Three Cole Foundation Transition Awards, for a total of $225,000, to allow the Institut Armand-Frappier, the Universitçİ de Montrçİal and McGill University and their affiliated medical research institutes to hire a postdoctoral researcher each for tenure-track or associate professor positions. * Some $572,000 to create a pediatric leukemia cell bank based at the Sainte-Justine University Hospital Research Center. In addition, the Cole Foundation will contribute $637,000 to allow the Quebec Leukemia Cell Bank to expand its operation and preserve adolescent leukemia cells that will be widely available to researchers. Building on prior investments This new support builds on the Cole Foundation"s Fellowship Programme, which was created to encourage young researchers in search of a cure for pediatric leukemia and related diseases. This year, the Cole Foundation is injecting another $425,000 to propel the work of another 13 Cole Fellows. Since 2007, the Cole Foundation has generously funded some 31 post-doctoral and graduate research fellowships at the three institutions. "The faculties of medicine at the Universitçİ de Montrçİal and McGill University, along with the Institut Armand-Frappier, produce scientists who are at the forefront of the international battle against pediatric leukemia," said Barry Cole, president of the Cole Foundation. "These new investments, coupled with our ongoing Cole Fellowships, will serve as important tools to empower tomorrow"s scientists - right here in Montreal - so they may find new ways to conquer pediatric leukemia and related diseases." 2009 Cole Fellows Of the 13 new recipients announced for 2009, 10 will work at Universitçİ de Montrçİal-affiliated institutions such as the Institute for Research in Immunology Cancer (IRIC), Sainte-Justine University Hospital Research Center and Maisonneuve-Rosemont Hospital. At McGill, three Cole Fellows will work from the affiliated McGill University Health Centre and Lady Davis Research Centre of the Jewish General Hospital. The newly announced 2009 Cole Fellows are: * Marie-Claude Bourgeois-Daigneault, PhD program, UdeM * Marie Cargnello, PhD program, UdeM * ç‰tienne Caron, PhD program, UdeM * Cindy Degerny, post-PhD program, McGill * Neda Delgoshaie, PhD program, UdeM * Cyrus Khandanpour, post-PhD program, UdeM * John Mills, PhD program, McGill * Ali Mokdad, post-PhD program, UdeM * Elena Shirokova, post-PhD program, UdeM * Marie-Claude Sincennes, PhD program, UdeM * Urmila Tawar, post-PhD program, McGill * Cçİdric Tremblay, post-PhD program, UdeM * Brian Wilhelm, post-PhD program, UdeM Sylvain-Jacques Desjardins University of Montreal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009